AMENDED CLAIMS

[received by the International Bureau on 10 November 2003 (10.11.03), original claims 1-24 replaced by new claims 1-21 (3 pages)]

1. An injectable aqueous composition for veterinary use containing a physiologically active salt of Carprofen (6-chloro-α-methyl-carbazole-2-acetic acid) in an amount of from about 0.5 to 30% (w/v) together with a poloxamer in an amount of from about 0.5 to 20% (w/v) and said injectable aqueous composition being stable at room temperature.

2. An injectable aqueous composition according to Claim 1 wherein said composition is room temperature stable for a minimum of 11 months.

3. An injectable aqueous composition according to Claims 1 or 2 wherein the poloxamer is $HO(CH_2CH_2O)_x(CCH_3HCH_2O)_y(CH2CH2)_zH$ wherein x is about 75, y is about 30 and z is about 75 or x is 98, y is 67 and z is 98.

4. An injectable aqueous composition according to Claim 3 wherein the carprofen salt is in the form of an arginine salt.

5. An injectable aqueous composition according to Claim 3 wherein the carprofen salt is in the form of a lysine salt.

6. An injectable aqueous composition according to any one of Claims 1 to 5 wherein the carprofen is present in an amount of from about 2.5 to 7.5% (w/v).

7. An injectable aqueous composition according to any one of Claims 1 to 5 wherein the carprofen is present in an amount of from about 2.5 to 5% (w/v).

8. An injectable aqueous composition according to any one of Claims 1-7 comprising arginine in an amount of from about 1 to 20% (w/v).

9. An injectable aqueous composition for veterinary use containing a physiologically active salt of Carprofen (6-chloro-α-methyl-carbazole-2-acetic acid), in an amount of from at least about 0.25% (w/v) together with a poloxmer in an

amount from about 0.5 to 20% (w/v) and said injectable aqueous composition being stable at room temperature.

10. An injectable aqueous composition according to Claim 9 wherein the poloxamer is present in an amount of from about 2 to 12% (w/v).

11. An injectable aqueous composition according to Claim 9 wherein an organic solvent is present with the poloxamer.

12. An injectable aqueous composition according to Claim 11 wherein the organic solvent is present in the range of 0.5 to 20% (w/v).

13. An injectable aqueous composition according to Claims 11 or 12 wherein the poloxamer is present in an amount of from 1% to 12% (w/v).

14. An injectable aqueous composition for veterinary use containing from about 0.25% to 30% (w/v) of carprofen arginine salt together with a poloxamer in an amount from about 0.5 to 20% (w/v) and said injectable aqueous composition being stable at room temperature.

15. An injectable aqueous composition for veterinary use according to claim 14 comprising arginine in an amount of from 1 to 20% (w/v).

16. An aqueous injectable composition comprising carprofen or a physiologically acceptable salt thereof in an amount of from 0.25% to 30% (w/v), a polymeric species selected from the group of polyoxypropylene/polyoxyethylene block co-polymers in the amount of from 0.5% to 20% (w/v), a preservative and water sufficient for injection and said injectable aqueous composition being stable at room temperature.

17. A method of producing a room-temperature stable injectable aqueous composition for veterinary use comprising bringing together an effective amount of carprofen or a physiologically acceptable salt thereof and a poloxamer, and adding sufficient water for injection.

18. A method according to Claim 17 wherein the poloxamer is $HO(CH_2CH_2O)_x(CCH_3HCH_2O)_y(CH_2CH_2)_zH$ wherein x is about 75, y is about 30 and z is about 75 or x is 98, y is 67 and z is 98.

19. A method of producing an injectable aqueous composition according to Claims 17 or 18 wherein said method further comprises the inclusion of a preservative.

20. An injectable aqueous composition for veterinary use according to any one of the Examples 1 to 19 hereinbefore.

21. A method of producing an injectable aqueous composition substantially as described in the Example 1.